Working… Menu

Master Rollover Protocol for Continued Safety Assessment of Study Drug

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02632994
Expanded Access Status : Available
First Posted : December 17, 2015
Last Update Posted : September 5, 2021
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Condition or disease Intervention/treatment
Cancer Drug: LY2503029 Drug: LY3023414

Layout table for study information
Study Type : Expanded Access
Official Title: Master Rollover Protocol for Continued Safety Assessment of Study Drug

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: LY2503029
    Administered orally.
  • Drug: LY3023414
    Administered orally.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion Criteria:

  • Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02632994

Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Layout table for location information
United States, California
UCLA Medical Center Available
Torrance, California, United States, 90505
Contact    310-325-8252      
Principal Investigator: Dr. Parvin Fatheddin Peddi         
United States, Indiana
Fort Wayne Oncology & Hematology Available
Fort Wayne, Indiana, United States, 46804
Contact    260-436-0800      
Principal Investigator: Dr. Sunil Babu         
United States, Tennessee
Sarah Cannon Cancer Center Available
Nashville, Tennessee, United States, 37203
Contact    615-329-7274      
Principal Investigator: Dr. Howard A. Burris III         
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST) Eli Lilly and Company
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT02632994    
Other Study ID Numbers: 16161
I8I-MC-JYAA ( Other Identifier: Eli Lilly and Company )
First Posted: December 17, 2015    Key Record Dates
Last Update Posted: September 5, 2021
Last Verified: September 1, 2021